The Bombay High Court has clarified a critical ambiguity in India’s pharmaceutical pricing regime, holding that the Drugs (Price Control) Order 2013 (DPCO 2013) imposes price ceilings only on formulations explicitly listed in its First Schedule. This ruling resolves long-standing disputes between manufacturers and the National Pharmaceutical Pricing Authority (NPPA) over the scope of price regulation for innovative drug delivery systems.
Background & Facts
The Dispute
The petitioners, M/s. Franco Indian Pharmaceuticals Pvt. Ltd. and the Indian Drug Manufacturers Association (IDMA), challenged the National Pharmaceutical Pricing Authority (NPPA) for issuing demand notices alleging overcharging on sustained release (SR) and controlled release (CR) formulations of drugs, including Glyciphage SR 500 mg tablet. The NPPA contended that since the active ingredient Metformin was listed in the First Schedule of DPCO 2013, all formulations containing Metformin - including SR variants - were subject to the ceiling price fixed for plain Metformin 500 mg tablets. The petitioners argued that SR/CR formulations, which use advanced biphasic polymer matrix technology to control drug release, are distinct dosage forms and cannot be deemed covered unless explicitly listed.
Key Facts
- The DPCO 2013 was notified on 15.05.2013, superseding DPCO 1995, and was issued under Section 3 of the Essential Commodities Act, 1955.
- The First Schedule to DPCO 2013 incorporated the National List of Essential Medicines (NLEM) 2011, listing specific formulations by generic name, strength, and dosage form.
- Metformin 500 mg tablets were included in the First Schedule via Order dated 21.06.2013, with a ceiling price of Rs. 1.56 per tablet.
- Glyciphage SR 500 mg tablet, a sustained release formulation of Metformin, was never listed in the First Schedule nor added by any subsequent order under DPCO 2013.
- The petitioner manufactured Glyciphage SR 500 mg using a biphasic polymer matrix diffusion technology, resulting in prolonged gastric residence and reduced side effects compared to immediate-release tablets.
- On 22.01.2014, NPPA issued a notice demanding compliance with the ceiling price for Glyciphage SR 500 mg, claiming it fell under the Metformin category.
- On 04.12.2014, NPPA issued a show cause notice alleging overcharging of Rs. 3,85,69,773/-.
- On 16.01.2015, NPPA issued a demand notice for Rs. 7,88,37,886/- with 15% interest, threatening recovery as arrears of land revenue under the Essential Commodities Act, 1955.
- The Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals) issued a clarification on 19/20.09.2013 stating that innovative dosage forms like SR/CR were not intended to be covered under price control unless specifically listed.
- The Ministry of Health and Family Welfare issued an office memorandum on 06.12.2013 clarifying that only conventional dosage forms (tablets, capsules, injections) listed in NLEM 2011 were covered, excluding modified release forms unless explicitly specified.
- The NPPA ignored these clarifications and continued to issue notices to manufacturers.
Procedural History
- 15.05.2013: DPCO 2013 notified.
- 21.06.2013: Order issued including Metformin 500 mg tablets in First Schedule with ceiling price.
- 19/20.09.2013: Ministry of Chemicals and Fertilizers clarifies that SR/CR formulations are not subject to price control unless specifically listed.
- 06.12.2013: Ministry of Health and Family Welfare issues memorandum excluding modified release forms from NLEM coverage.
- 22.01.2014: NPPA issues notice to Franco Indian Pharmaceuticals regarding Glyciphage SR 500 mg.
- 04.12.2014: NPPA issues show cause notice for alleged overcharging.
- 16.01.2015: NPPA issues demand notice for Rs. 7,88,37,886/-.
- 24.03.2015: Bombay High Court issues notice and grants interim stay on coercive action.
- 2015: Writ Petition No. 2216 of 2015 and Writ Petition No. 885 of 2015 filed.
- 07.03.2026: Judgment reserved.
- 10.04.2026: Judgment pronounced.
The Parties' Positions
Petitioners (Franco Indian Pharmaceuticals & IDMA): Argued that DPCO 2013 defines "scheduled formulation" strictly as those explicitly listed in the First Schedule. SR/CR formulations are distinct pharmaceutical products requiring separate inclusion. The Ministry’s clarifications and pattern of subsequent orders (e.g., for Nifedipine SR, Diclofenac SR) confirm that inclusion requires explicit action.
Respondents (Union of India & NPPA): Contended that any formulation containing a scheduled drug (e.g., Metformin) is automatically covered, regardless of delivery system. They argued that NLEM’s purpose is public procurement, not pricing, and that NPPA’s interpretation ensures price control over essential medicines.
Relief Sought
The petitioners sought:
- Quashing of the NPPA’s demand notice dated 16.01.2015.
- Declaration that Glyciphage SR 500 mg is not subject to ceiling price under DPCO 2013.
- Direction to NPPA to cease all coercive actions against manufacturers of non-scheduled SR/CR formulations.
- Costs of litigation.
The Legal Issue
The central question was whether DPCO 2013 imposes a ceiling price on a pharmaceutical formulation merely because its active ingredient is listed in the First Schedule, or whether the formulation itself - considering its dosage form and drug delivery system - must be explicitly specified in the Schedule.
Arguments Presented
For the Appellant/Petitioner
The petitioners relied on the plain language of DPCO 2013, particularly definitions of "scheduled formulation" and "non-scheduled formulation" under Paragraph 2(zb) and (v). They emphasized that the First Schedule lists formulations by specific strength and dosage form, and that the Ministry of Chemicals and Fertilizers had consistently acted on this principle by issuing separate orders to include SR/CR variants (e.g., Nifedipine SR 10 mg, Diclofenac SR 50 mg). They cited the Ministry’s 19/20.09.2013 letter and the Ministry of Health’s 06.12.2013 memorandum as authoritative interpretations. They also relied on Pfizer Ltd. v. Union of India (2025 SCC OnLine Bom 3821), where this Court held that sustained release tablets are distinct from conventional tablets and cannot be presumed covered unless explicitly listed.
For the Respondent/State
The respondents argued that the policy objective of DPCO 2013 is to ensure affordability of essential medicines, and that excluding SR/CR formulations would create a loophole. They contended that the First Schedule’s reference to "formulations" includes all variants of a scheduled drug, and that the Ministry’s clarifications were internal administrative notes not binding on NPPA. They relied on Union of India v. Cynamide India Ltd. (1987) and Glaxosmithkline v. Union of India (2014), asserting that courts should defer to expert regulatory bodies on pricing matters.
The Court's Analysis
The Court undertook a detailed textual and contextual analysis of DPCO 2013, beginning with its foundational policy shift under the National Pharmaceutical Pricing Policy 2012, which explicitly moved from controlling bulk drugs to controlling only formulations. The Court emphasized that the definitions in Paragraph 2 are precise: "scheduled formulation" means a formulation included in the First Schedule, and "non-scheduled formulation" means one not included.
"The definition of 'scheduled formulation' under Paragraph 2(zb) is unambiguous: it refers only to those formulations included in the First Schedule. There is no implied inclusion of variants based on active ingredient alone."
The Court examined the pattern of subsequent orders issued by the Ministry of Chemicals and Fertilizers. For instance, Nifedipine 10 mg tablets were added on 14.06.2013; Nifedipine SR 10 mg on 28.06.2013; Nifedipine SR 20 mg on 05.07.2013; and Nifedipine SR capsules on 20.09.2013. Each required a separate order. This demonstrated a deliberate, step-by-step process for inclusion. The absence of any such order for Glyciphage SR 500 mg meant it remained a non-scheduled formulation.
The Court rejected the respondents’ argument that NLEM’s purpose was limited to public procurement, noting that DPCO 2013 explicitly incorporated NLEM 2011 as its First Schedule, thereby adopting its structure and intent. The Ministry of Health’s 06.12.2013 memorandum, which excluded modified release forms unless specified, was held to be a consistent and authoritative interpretation.
The Court distinguished T.C. Healthcare v. Union of India (2020), which concerned DPCO 1995, noting that DPCO 2013 marked a clear departure from prior regimes by introducing explicit formulation-level control. The Court also affirmed the relevance of Pfizer Ltd., observing that its reasoning on distinct drug delivery systems aligned with the statutory scheme.
"To hold otherwise would render the entire structure of the First Schedule meaningless. If every variant of a scheduled drug were automatically covered, there would be no need for the Ministry to issue dozens of subsequent orders adding SR and CR formulations."
The Court found the NPPA’s actions arbitrary and in direct conflict with the parent Ministry’s interpretation, thereby justifying judicial intervention under Article 226.
The Verdict
The petitioners succeeded. The Court allowed Writ Petition No. 885 of 2015 in full and Writ Petition No. 2216 of 2015 on the principal prayer. The NPPA’s demand notice dated 16.01.2015 is quashed. The Court held that the notification dated 21.06.2013 for Metformin 500 mg tablets cannot be the basis for imposing a ceiling price on Glyciphage SR 500 mg. All coercive actions, including recovery proceedings under the Essential Commodities Act, 1955, against manufacturers of non-scheduled SR/CR formulations are permanently stayed. The Court directed the NPPA to cease all such demands and to revise its internal guidelines to align with DPCO 2013’s explicit terms.
What This Means For Similar Cases
Formulation-Specific Inclusion Is Mandatory
- Practitioners must now argue that any claim of overcharging against a sustained release, controlled release, or modified dosage formulation is invalid unless that exact formulation is listed in the First Schedule.
- Manufacturers may rely on the Ministry’s 2013 clarifications and the pattern of subsequent orders to defend against NPPA notices.
NPPA Cannot Override Parent Ministry’s Interpretation
- Regulatory bodies like NPPA cannot unilaterally expand the scope of statutory instruments when the parent ministry has issued a clear, consistent interpretation.
- Internal administrative notes or circulars from the parent ministry carry legal weight in interpreting ambiguous statutory provisions.
Precedent for Future Drug Innovation
-
Pharmaceutical companies developing novel delivery systems (e.g., transdermal patches, inhalers, or extended-release capsules) can now operate with greater certainty that innovation does not automatically trigger price control.
-
Future amendments to DPCO 2013 must follow the established procedure: explicit inclusion via order under Paragraph 17, not implied extension.
-
Always verify whether the specific dosage form (e.g., SR, CR, dispersible) is listed in the First Schedule - not just the active ingredient.
-
If a formulation is not listed, challenge NPPA notices on grounds of ultra vires action under DPCO 2013.
-
Cite Pfizer Ltd. v. Union of India and the Ministry’s 2013 clarifications as binding interpretative aids.
